Rapamune (Sirolimus) therapy allows for effective withdrawal of Cyclosporine in kidney transplant patients

@ RAPAMUNE (SIROLIMUS) THERAPY ALLOWS FOR EFFECTIVE WITHDRAWAL OF CYCLOSPORINE IN KIDNEY TRANSPLANT PATIENTS -- International Study Confirms Rapamune-treated Patients Fare Well and Avoid Exposure to the Long-term Dangerous Side Effects of Cyclosporine -- ROME, 31 August, 2000 -- Kidney transplant patients can be effectively treated with the new anti-rejection medication Rapamune (sirolimus) as the long-term primary therapy, permitting the withdrawal of the conventional immunosuppressant cyclosporine, a drug associated with a number of serious adverse effects such as kidney damage,